Table 2. Treatment Exposurea.
| Phase | No. of Injections, Mean (95% CI) | Count Ratio (95% CI) | P Value | |
|---|---|---|---|---|
| Combination Group (n = 29) | Ranibizumab Alone Group (n = 29) | |||
| Loading phase (month 1 to month 6) | 5.5 (4.7-6.5) | 5.7 (4.9-6.7) | 0.96 (0.77-1.20) | .74 |
| Total maintenance phase (month 7 to month 24) | 3.2 (2.5-3.8) | 7.1 (6.0-8.0) | 0.46 (0.36-0.61) | <.001 |
| Early maintenance phase (month 7 to month 13) | 1.5 (1.1-2.0) | 2.4 (1.9-3.1) | 0.60 (0.41-0.88) | .01 |
| Late maintenance phase (month 13 to month 24) | 1.7 (1.3-2.2) | 4.6 (3.8-5.5) | 0.37 (0.26-0.51) | <.001 |
a
Based on regression analysis.